OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ...
Verywell Health on MSN

Proteinuria in complement 3 glomerulopathy: Why it matters and what to do

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Proteinuria affects most people with complement 3 glomerulopathy ...
Verywell Health on MSN

How complement 3 glomerulopathy is diagnosed: Step-by-step

Medically reviewed by Jamin Brahmbhatt, MD Key Takeaways Complement 3 glomerulopathy (C3G) is diagnosed with a combination of ...

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
Frontiers

The inflammation-cancer nexus: Unlocking novel strategies for immunomodulation and therapy

The relationship between inflammation and cancer represents one of the central paradoxes in modern tumor immunology. On one hand, chronic inflammation is a ...